Essential diagnostic imaging agents to help identify disease and improve patient care
Improved diagnostic information for better patient management
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
Lantheus and Progenics Agree to Amended Transaction Terms
Lantheus Holdings to Present at the 9th Annual SVB Leerink Global Healthcare Conference
We want to provide you with important information regarding our response to the COVID-19 pandemic.
(updated 3/24/2020)
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
Lantheus and Progenics Agree to Amended Transaction Terms
Lantheus Holdings to Present at the 9th Annual SVB Leerink Global Healthcare Conference
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.